MARAT SHPOLYANSKY: Open Payments
NPI 1932450954 · BURBANK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$629 in 44 payments from 7 companies in 2025. Trend: 2023 $855 · 2024 $1,076 · 2025 $629
Food & beverage: $629
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 32 | $352 |
| Alkermes, Inc. | 5 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $64 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Neurocrine BioSciences, Inc. | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $16 |
Products named: INVEGA SUSTENNA, ARISTADA, CAPLYTA, ABILIFY MAINTENA, INGREZZA, FANAPT, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
